Research Topics
| Giuseppe LapadulaSummaryCountry: Italy Publications
| Collaborators
|
Detail Information
Publications
Prevalence and risk factors for etravirine resistance among patients failing on non-nucleoside reverse transcriptase inhibitorsGiuseppe Lapadula
Clinic for Infectious Diseases and Tropical Medicine, University of Brescia, Brescia, Italy
Antivir Ther 13:601-5. 2008..Prevalence and factors associated with etravirine (EW) resistance mutations among patients failing on first-generation non-nucleoside reverse transcriptase inhibitors (NNRTI) merit investigation...- Updated prevalence of genotypic resistance among HIV-1 positive patients naïve to antiretroviral therapy: a single center analysisGiuseppe Lapadula
Institute of Infectious and Tropical Diseases, University of Brescia, Brescia, Italy
J Med Virol 80:747-53. 2008..38; 95% CI:0.17-0.86; P = 0.020). Prevalence of primary resistance mutations suggests that genotypic resistance testing should be performed before starting treatment in naïve patients in Italy, particularly when NNRTI are prescribed... - Analysis of severe hepatic events associated with nevirapine-containing regimens: CD4+ T-cell count and gender in hepatitis C seropositive and seronegative patientsCarlo Torti
School of Medicine, Institute for Infectious and Tropical Diseases, University of Brescia, Brescia, Italy
Drug Saf 30:1161-9. 2007..Moreover, the predictive value of gender and CD4+ T-cell count on the risk of raised transaminase levels has been poorly investigated in populations of patients co-infected with hepatitis C virus (HCV)... - Evidence of long-term suppression of hepatitis B virus DNA by tenofovir as rescue treatment in patients coinfected by HIVEugenia Quiros-Roldan
Institute for Infectious and Tropical Diseases, University of Brescia, Brescia, Italy
Antivir Ther 13:341-8. 2008..The efficacy of long-term hepatitis B virus (HBV) treatment with tenofovir (TDF) in relation to lamivudine (LMV) resistance in HIV patients failing on LMV deserves further investigations... - Influence of genotype 3 hepatitis C coinfection on liver enzyme elevation in HIV-1-positive patients after commencement of a new highly active antiretroviral regimen: results from the EPOKA-MASTER CohortCarlo Torti
Istituto di Malattie Infettive e Tropicali, Universita di Brescia, Brescia, Italy
J Acquir Immune Defic Syndr 41:180-5. 2006..The independent role of hepatitis C virus (HCV) genotype 3 in liver transaminase elevation following highly active antiretroviral regimens is still controversial... - Predictors of clinical progression among HIV-1-positive patients starting HAART with CD4+ T-cell counts > or =200 cells/mm3Giuseppe Lapadula
Institute for Infectious and Tropical Diseases, University of Brescia, Italy
Antivir Ther 12:941-7. 2007..Baseline and follow-up predictors of new AIDS-defining events (ADE) or death among patients who started HAART with CD4+ T-cell counts > or =200 cells/mm3 have rarely been assessed simultaneously... - Screening and Management of HIV-2-Infected Individuals in Northern ItalySilvia Costarelli
Institute of Infectious and Tropical Diseases, University of Brescia, Brecia, Italy
AIDS Patient Care STDS 22:489-94. 2008..Accurate screening programs and integration of virological tools must be implemented urgently, given the high prevalence of HIV-2, particularly in immigrant patients... - Plasma HIV load and proviral DNA decreases after two standard antiretroviral regimens in HIV-positive patients naïve to antiretroviralsCarlo Torti
Institute for Infectious and Tropical Diseases, University of Brescia, Brescia, Italy
Curr HIV Res 6:43-8. 2008..Further studies are needed to compare pVL decay between antiretroviral regimens and assess whether proviral HIV-DNA load is a surrogate marker of treatment effectiveness... - Predictors of AIDS-defining events among advanced naïve patients after HAARTCarlo Torti
Institute for Infectious and Tropical Diseases, University of Brescia, Italy
HIV Clin Trials 8:112-20. 2007..Baseline and follow-up predictors of new AIDS-defining events or death (ADE/death) among patients who started HAART late in their disease history have rarely been assessed simultaneously... - Influence of hepatitis C genotypes on lipid levels in HIV-positive patients during highly active antiretroviral therapyGiuseppe Lapadula
Istituto per le Malattie Infettive e Tropicali, , Brescia, Italy
Antivir Ther 11:521-7. 2006..This effect was particularly attributed to HCV-3, which was the only genotype associated with lower triglyceridaemia during HAART... - Influence of folate serum concentration on plasma homocysteine levels in HIV-positive patients exposed to protease inhibitors undergoing HAARTMaria Cristina Uccelli
Institute for Infectious and Tropical Diseases, University of Brescia, Brescia, Italy
Ann Nutr Metab 50:247-52. 2006..Homocysteinemia (Hcy) increase and risk factors in HIV-positive patients are not clear yet... - Adherence and plasma drug concentrations are predictors of confirmed virologic response after 24-week salvage highly active antiretroviral therapyEugenia Quiros Roldan
Institute for Infectious and Tropical Diseases, University of Brescia, Brescia, Italy
AIDS Patient Care STDS 21:92-9. 2007..4; 95% CI 0.2-0.8; p = 0.014) were both negative independent predictors of sustained virologic response, while the use of boosted protease inhibitor-containing regimens resulted to be protective (OR: 2.4; 95% CI 1.1-5.3; p = 0.032)... - Influence of viral chronic hepatitis co-infection on plasma drug concentrations and liver transaminase elevations upon therapy switch in HIV-positive patientsCarlo Torti
Institute for Infectious and Tropical Diseases, University of Brescia, p le Spedali Civili 1, 25123 Brescia, Italy
Int J Antimicrob Agents 29:185-90. 2007..The presence of HCV and/or HBV co-infections correlated with higher plasma drug concentrations, although it did not appear to influence hepatotoxicity risk... - CD4+ T cell evolution and predictors of its trend before and after tenofovir/didanosine backbone in the presence of sustained undetectable HIV plasma viral loadCarlo Torti
Universita degli Studi di Brescia, p le Spedali Civili 1, Brescia, Italy
J Antimicrob Chemother 59:1141-7. 2007..We investigated whether tenofovir plus didanosine at a weight-adjusted dosage could be responsible for such an effect, and factors associated with CD4 + T cell count evolution under this combination... - Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTICarlo Torti
University of Brescia, Italy
BMC Infect Dis 11:23. 2011..Data regarding CD4+ recovery after switching from protease inhibitor (PI)-based regimens to regimens not containing PI are scarce... - Prediction of early and confirmed virological response by genotypic inhibitory quotients for lopinavir in patients naïve for lopinavir with limited exposure to previous protease inhibitorsCarlo Torti
Institute for Infectious and Tropical Diseases, University of Brescia, School of Medicine, Piazzale Spedali Civili 1, 25123 Brescia, Italy
J Clin Virol 35:414-9. 2006..To determine the impact of genotypic inhibitory quotient (GIQ) for lopinavir (LPV) in patients failing HAART with limited antiretroviral exposure... - Dideoxynucleoside HIV reverse transcriptase inhibitors and drug-related hepatotoxicity: a case reportGiuseppe Lapadula
Institute of Infectious and Tropical Diseases, University of Brescia, Italy
J Med Case Reports 1:19. 2007..Liver biopsy may provide further important information regarding patients with severe transaminase elevation, for a better understanding of the etiology of liver damage... - A randomized, pilot trial to evaluate glomerular filtration rate by creatinine or cystatin C in naive HIV-infected patients after tenofovir/emtricitabine in combination with atazanavir/ritonavir or efavirenzLaura Albini
Department of Materno Infantile e Tecnologie Biomediche, Institute of Infectious and Tropical Diseases, University of Brescia, Italy
J Acquir Immune Defic Syndr 59:18-30. 2012..There is lack of data on GFR estimated by these methods in patients on highly active antiretroviral therapy... - Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER CohortCarlo Torti
Istituto di Malattie Infettive e Tropicali, Universita degli Studi di Brescia, p le Spedali Civili 1, Brescia, Italy
BMC Infect Dis 5:58. 2005.... - Risk of early virological failure of once-daily tenofovir-emtricitabine plus twice-daily nevirapine in antiretroviral therapy-naive HIV-infected patientsGiuseppe Lapadula
Clin Infect Dis 46:1127-9. 2008 - No evidence of relation between peripheral neuropathy and presence of hemochromatosis gene mutations in HIV-1-positive patientsSilvia Costarelli
J Acquir Immune Defic Syndr 46:255-6. 2007